Tag: PhD1

Poster-Imaging

Influence of Imaging Parameters on MRI Contrast Using Qualitymetrix

Background: Acquiring brain magnetic resonance images (MRI) with sufficient tissue contrast is important for supporting diagnosis and...

Read More

Poster-Methods of Care

Impact of the COVID-19 Pandemic on People with Multiple Sclerosis: Results from an International Survey

Background: The broad impact of the COVID-19 pandemic on people with multiple sclerosis (PwMS) and their health, behaviors, and ability to...

Read More

Poster-Internet and Information Services

Passive Monitoring of Cognition Using a Smartphone Application in MS

Background: Cognitive impairment is one of the most common and debilitating symptoms of multiple sclerosis (MS). Traditional...

Read More

Poster-Imaging

Could Cerebral Autoregulatory Collapse Explain Cognitive Impairment in MS?

Background: Cognitive impairment occurs in almost 70% of multiple sclerosis (MS) patients. The pathophysiology of this impairment is...

Read More

Poster-Imaging

Compliance of a Real-World Dataset with the CMSC 2018 Guidelines

Background: Acquiring brain magnetic resonance images (MRI) in a standardized way, following CMSC guidelines, increases image consistency...

Read More

Poster-Imaging

Neural Correlates of Hand Motor Function Revealed By Structural MR Imaging: A Smartphone-Based Remote Assessment Study in People with MS

Background: Regional gray matter pathology is associated with hand motor impairment in people with multiple sclerosis (PwMS). Objectives:...

Read More

Poster-Disease-modifying Therapy

Online Medical Education Increases Knowledge Among Neurologists of Safety Considerations for Disease Modifying Therapies in Multiple Sclerosis

Background: Disease modifying therapies (DMTs) have transformed the management of multiple sclerosis (MS). Patients can now live many years...

Read More

Poster-Disease-modifying Therapy

Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study

Background: In a 48-week Phase II study NCT02975349, in patients with relapsing multiple sclerosis, evobrutinib was generally...

Read More

Poster-Disease-modifying Therapy

Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study

Background: Siponimod showed beneficial effects on magnetic resonance imaging (MRI) lesion activity, total brain and gray matter (GM)...

Read More

Poster-Disease-modifying Therapy

Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying As Hispanic from the Expand Study

Background: In the Phase 3 EXPAND trial siponimod, a selective S1P receptor modulator, significantly reduced risk of 3-month and 6-month...

Read More